Searchable abstracts of presentations at key conferences on calcified tissues

ba0004p116 | (1) | ICCBH2015

Osteopetrosis with uncommon final height: can only local IGF1 hold normal growth during pubertal spurt?

Milani Soraya Sader , Paula Francisco Jose , Liberatore Jr Raphael , Martinelli Jr Carlos Eduardo

Background: Final stature is a result of concomitant growth hormone (GH)-IGF1 axis integrity, a healthy environment and genetic background. Occasionally, growth occurs despite remarkable impairment in hormone profile. Presenting problem: An uncommon case of longitudinal growth in a boy with very low IGF1 concentrations and clinical diagnosis of osteopetrosis. Clinical management: We report on the case of a 19 year-old male patient with the diagnosis of osteopetrosis who had a ...

ba0002p181 | (1) | ICCBH2013

Long-term imiglucerase/alglucerase treatment in Latin American children with type 1 Gaucher disease: lessons from the International Collaborative Gaucher Group (ICGG) Gaucher Registry

Camelo Jr Jose Simon , Cabello Juan Francisco , Drelichman Guillermo G , Kerstenetzky Marcelo M , Sarmiento Isabel C , Linares Adriana

Objective: Evaluate the clinical characteristics of all Latin American pediatric patients with Gaucher disease type 1 (GD1) enrolled in the ICGG Gaucher Registry at baseline and investigate long-term outcomes and clinical benefit of prolonged imiglucerase/alglucerase therapy in patients with manifestations of GD1 at baseline.Methods: All Latin American patients with GD1 in the ICGG Gaucher Registry (NCT00358943) who were <18 years of age at the start...

ba0007p15 | (1) | ICCBH2019

TA-46 prevents premature synchondrosis and restores foramen magnum size in a mouse model of achondroplasia

Garcia Stephanie , Rignol Guylene , Goncalves Diogo , Dellugat Pierre , Tosello Lionel , Marsault Raphael , Stavenhagen Jeff , Santarelli Luca , Gouze Elvire

Objectives: Achondroplasia, the most common form of short limb dwarfism, is a rare genetic disorder caused by a gain-of-function mutation of the FGFR3 receptor (FGFR3-G380R) and there are currently no effective treatments available. We have developed TA-46, a recombinant human soluble FGFR3(sFGFR3) form of the FGFR3 cell surface receptor containing an extra-cellular ligand-binding domain, including three IgG domains, which confer binding specificity. TA-46 is designed to block...

ba0002oc13 | Diagnostics | ICCBH2013

Level of calcium intake modifies the correlation between parathyroid hormone and 25-hydroxyvitamin D: a proposal of adequate 25-hydroxyvitamin D levels in children

Reyes Maria Loreto , Molina Marcela , Escobar Raul , Hernandez Maria Isabel , Cavada Gabriel , Jr Camargo Carlos Arturo

Background: The ‘adequate’ level of 25-hydroxyvitamin D (25OHD) in children remains unclear. For bone outcomes, parathyroid hormone (PTH) is an important functional biomarker. Prior studies have shown too weak a correlation between 25OHD and PTH levels to determine adequate 25OHD level.Objective: To determine adequate 25OHD level(s) in children using a normal PTH value of 65 pg/ml while adjusting for calcium intake.Design...

ba0001pp470 | Other diseases of bone and mineral metabolism | ECTS2013

Determinants of bone loss in cystic fibrosis

Gensburger Deborah , Chapurlat Roland , Nove-Josserand Raphaele , Rabilloud Muriel , Durieu Isabelle

Objectives: Bone disease is now well described in cystic fibrosis adult patients. CF bone disease is multifactorial but many studies suggested the crucial role of inflammation and chronic pulmonary infection. The objectives of this study were to assess the prevalence of osteoporosis in a current adult CF population and to examine its relationship with infections and inflammation.Methods: Patients were recruited in the adult CF Lyon Centre and assessed in...

ba0005cabs.oc3.4 | Oral Communications | ECTS2016

Anti-sclerostin treatment prevents multiple myeloma bone disease and reduces tumour burden

McDonald Michelle , Reagan Michaela , Terry Rachael , Pettitt Jessica , Le Lawrence , Mohanty Sindhu , Kramer Ina , Kneissel Michaela , Brooks Daniel , Cheng Tegan , Little David , Bouxsein Mary , Rosen Cliff , Ghobrial Irene , Croucher Peter

Multiple myeloma is characterized by extensive bone marrow tumour and destructive osteolytic lesions. Both increased bone resorption and suppressed bone formation result in lesions and pathological fractures. Anti-resorptive therapies prevent further bone loss but patients continue to fracture, arguing for new therapies which increase bone strength. Anti-Sclerostin (Anti-Scl) is a potent stimulator of bone formation, is currently in clinical trials for osteoporosis, however it...